Search
for
Sort by
Research 841–870 of 1000+
- Geriatric Dermatologic Therapy
- Docosahexaenoic acid-acylated astaxanthin esters alleviate cisplatin- induced acute kidney injury by modulating the ferroptosis-related GPX4/xCT signaling pathway and reducing oxidative stress
- The Impact of LED Therapy on Skin: The Review
- Immunological control of skin development: from homeostasis to developmental pathologies
- Evaluation of the palatal wound healing effect of wound dressing carrying GSK-3 antagonist tideglusib on rats
- The role of integrin alphavbeta6 in impaired wound healing and hair follicle regeneration
- 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
- When JAK inhibitors are off the table: durable remission of severe alopecia areata with dexamethasone oral mini-pulse and a focused review
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Sustaining treatment response in alopecia areata through tofacitinib dose tapering: A single-center retrospective study
- Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis
- Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response
- 681 Inhibition of STAT3, using Oenocarpus bataua vegetable oil, on in vitro model
- Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases
- Palmoplantar pustulosis–like eruption following tofacitinib therapy for juvenile idiopathic arthritis
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
- Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
- Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Clinical response to oral tofacitinib in pediatric patients with alopecia areata
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- Successful treatment of alopecia universalis with abrocitinib: a case report
- Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
- Most men choose eyebrows versus scalp hair: Response to Mostaghimi et al., “Evaluation of eyebrow and eyelash regrowth and patient satisfaction in the phase 3 THRIVE-AA2 trial of deuruxolitinib in adult patients with alopecia areata”
- JAK Inhibitors in the Treatment of Alopecia Areata: Efficacy, Safety, and Long-term Outcomes
- Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universalis
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients